Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pharming Group (PHARM) Fair Value & Analysis

Healthcare · NL · Market cap €813M

Price€1.16
Fair Value€0.4100
Upside-64.6%
Quality95/100
Evidence: High Range €0.3000 – €0.5200

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Pharming Group (PHARM) currently trades at €1.16, while our model-based Fair Value estimate is €0.4100 — implying the stock looks roughly 64.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Pharming Group (PHARM) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.4100 versus a price of €1.16 — about −65% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PHARM?
Our 21-model fair value for Pharming Group is €0.4100 (as of Jun 24, 2026), built from audited fundamentals. The current price is €1.16.
What is the quality score of PHARM?
Pharming Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.